Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma

BACKGROUND: Diffuse large B cell lymphoma (DLBCL) is the most common form of lymphoma. Although durable remissions can be achieved in more than half of these patients, DLBCL remains a significant clinical challenge, with approximately 30% of patients not being cured. BCR-associated kinases (SYK, BTK...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yizi, Li, Jiao, Ding, Ning, Wang, Xiaogan, Deng, Lijuan, Xie, Yan, Ying, Zhitao, Liu, Weiping, Ping, Lingyan, Zhang, Chen, Song, Yuqin, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379963/
https://www.ncbi.nlm.nih.gov/pubmed/30777096
http://dx.doi.org/10.1186/s13046-019-1076-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379963/
https://www.ncbi.nlm.nih.gov/pubmed/30777096
http://dx.doi.org/10.1186/s13046-019-1076-4

Ejemplares similares